Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling

Regulatory Toxicology and Pharmacology

Volumn 58, Issue 2, 2010, Pages 252-258

  Takano, Ryohji ^a,b   Murayama, Norie ^a   Horiuchi, Kana ^a   Kitajima, Masato ^b   Kumamoto, Masatoshi ^c   Shono, Fumiaki ^c   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b Fujitsu Kyusyu Systems   (Japan)

^c Japan Chemical Industry Associations (JCIA)   (Japan)

Author keywords

Biomonitoring; Cytochrome P450; Human liver microsomes; No observed adverse effect level; Physiologically based biokinetic modeling; Simulation

Indexed keywords

ACRYLONITRILE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; COMPUTER MODEL; CONTROLLED STUDY; EXPERIMENTAL MODEL; GAS CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; LIVER CLEARANCE; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICOKINETICS; URINE LEVEL;

ACRYLONITRILE; ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; SPECIES SPECIFICITY;

RATTUS;

EID: 77957326586     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.06.008     Document Type: Article

References (23)

1. Amidon G.L., Sinko P.J., Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 1988, 5:651-654.
2. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 2004, 79:381-393.
3. Cole P., Mandel J.S., Collins J.J. Acrylonitrile and cancer: a review of the epidemiology. Regul. Toxicol. Pharmacol. 2008, 52:342-351.
4. Collins F.S., Gray G.M., Bucher J.R. Toxicology. Transforming environmental health protection. Science 2008, 319:906-907.
5. Edwards S.W., Preston R.J. Systems biology and mode of action based risk assessment. Toxicol. Sci. 2008, 106:312-318.
6. Emoto C., Murayama N., Rostami-Hodjegan A., Yamazaki H. Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica 2009, 39:227-235.
7. Gargas M.L., Andersen M.E., Teo S.K.O., Batra R., Fennell T.R., Kedderis G.L. A physiologically based dosimetry description of acrylonitrile and cyanoethylene oxide in the rat. Toxicol. Appl. Pharmacol. 1995, 134:185-194.
8. Guengerich F.P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21:70-83.
9. Guengerich F.P., Geiger L.E., Hogy L.L., Wright P.L. In vitro metabolism of acrylonitrile to 2-cyanoethylene oxide, reaction with glutathione, and irreversible binding to proteins and nucleic acids. Cancer Res. 1981, 41:4925-4933.
10. Haber L.T., Patterson J. Report of an independent peer review of an acrylonitrile risk assessment. Hum. Exp. Toxicol. 2005, 24:487-527.
11. Hayes K.R., Bradfield C.A. Advances in toxicogenomics. Chem. Res. Toxicol. 2005, 18:403-414.
12. Kato M., Shitara Y., Sato H., Yoshisue K., Hirano M., Ikeda T., Sugiyama Y. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm. Res. 2008, 25:1891-1901.
13. Kirman C.R., Sweeney L.M., Gargas M.L., Strother D.E., Collins J.J., Deskin R. Derivation of noncancer reference values for acrylonitrile. Risk Anal. 2008, 28:1375-1384.
14. Leng, G., 2009. The importance of biomonitoring in place under a chemical accident. In: 49th Annual Congress of German Society of Occupational and Environmental Medicine, p. 118 (in German).
15. Murayama N., Kaneko N., Horiuchi K., Ohyama K., Shimizu M., Ito K., Yamazaki H. Cytochrome P450-dependent drug oxidation activity of liver microsomes from microminipigs, a possible new animal model for humans in non-clinical studies. Drug Metab. Pharma. 2009, 24:404-408.
16. National Research Council of the National Academies Toxicity Testing in the 21st Century: A Vision and a Strategy 2007, The National Academies Press, Washington, DC.
17. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 1964, 239:2370-2378.
18. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 2002, 91:129-156.
19. Sweeney L.M., Gargas M.L., Strother D.E., Kedderis G.L. Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol. Sci. 2003, 71:27-40.
20. Wild C.P. Complementing the genome with an exposome: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidem. Biomar. Prevent. 2005, 14:1847-1850.
21. Yamazaki H., Mimura M., Sugahara C., Shimada T. Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7α- and coumarin 7-hydroxylations. Biochem. Pharmacol. 1994, 48:1524-1527.
22. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Exp. Purif. 2002, 24:329-337.
23. Yamazaki H., Shimizu M., Nagashima T., Minoshima M., Murayama N. Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metab. Dispos. 2006, 34:1803-1905.